According to a news source, recent takeovers of India’s key drug companies by foreign pharmaceutical interests have policymakers worried about the potential impact on domestic drug markets and prices. The Indian companies, such as Ranbaxy Laboratories, Dabur Pharma, Shantha Biotech, and Orchid Chemicals and Pharmaceuticals, produce a majority of the less expensive generic drugs and vaccines used in the country and in other developing nations. A paper recently circulated by the commerce ministry reportedly noted that the takeovers “will further orient [Indian drug makers] away from the Indian market, thus reducing domestic availability of the drugs being produced by them.” Other policy analysts apparently suggest that fragmentation in the market keeps competition high and prices low and that the government has the authority to control excessive drug prices. See Nature Medicine, February 4, 2011.